In the report of the trial comparing two doses of REGEN-COV vs. placebo, in which the composite of 29 days covid-19 related hospitalization or death was the primary outcome, the following statement summarised the primary outcome results:
“Covid-19–related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%) (relative risk reduction [1 minus the relative risk], 71.3%; 95% confidence interval [CI], 51.7 to 82.9; P<0.001); these outcomes occurred in 7 of 736 patients in the REGEN-COV 1200-mg group (1.0%) and in 24 of 748 patients in the placebo group who underwent randomization concurrently (3.2%) (relative risk reduction, 70.4%; 95% CI, 31.6 to 87.1; P=0.002)”
And the authors conclude:
“The data from this phase 3 trial involving outpatients with Covid-19 showed that the 1200-mg dose of REGEN-COV, like the 2400-mg dose, reduced the risk of Covid-19–related hospitalization or death and sped the time to recovery.”
I find the results and conclusions misleading, since five patients died during the trial, 1 in the 2400mg group ,1 In the 1200 mg group and 3 In the placebo group, so that the experienced primary outcome was almost totally COVID related hospitalization and not death.
Would like to know what others think of these results and the authors interpretation.